March 13, 2026
1 min read

‘Manufacturing is access’: How Gilead’s early production moves set PrEP med Yeztugo up for success

From its 17-year development cycle through to its commercial launch, production has always been in Yeztugo’s DNA. And, for the twice-yearly pre-exposure prophylaxis medication—which Gilead Sciences has positioned as a key tool in the fight to end the HIV epidemic—“manufacturing is access.”

Leave a Reply

Your email address will not be published.

Previous Story

Feeling tired, achy, or weak? Expert says low vitamin D could be the cause, here’s how sunlight, nutrition, and doctor-guided supplements can help

Next Story

Younger Stroke Survivors Face Unique Mental Health Hurdles MedNews

Previous Story

Feeling tired, achy, or weak? Expert says low vitamin D could be the cause, here’s how sunlight, nutrition, and doctor-guided supplements can help

Next Story

Younger Stroke Survivors Face Unique Mental Health Hurdles MedNews

Latest from Blog

ROFI Drives New Approach to Crop Nutrition

With input costs continuing to pressure farm budgets, some growers are making difficult decisions to reduce fertilizer application rates. While that strategy may ease upfront expenses, it is also accelerating a broader
Go toTop